Purchase this article with an account.
filofteia Tacea, Leonidas Makris, Ahmed Kamal; One year retrospective analysis of ocriplasmin for the treatment of symptomatic vitreomacular traction. Invest. Ophthalmol. Vis. Sci. 2017;58(8):224. doi: https://doi.org/.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate the efficacy and safety of a single intravitreal injection of ocriplasmin in symptomatic patients with vitreomacular traction (VMT).
Retrospective analysis of all patients with symptomatic metamorphopsia, micro-scotomas and deterioration of vision secondary to VMT, confirmed with Spectral Domain Optical Coherence Tomography (SD-OCT). Patients received a single injection of ocriplasmin (JETREA®). LogMAR visual acuity, measurement of intraocular pressure (IOP) and SD-OCT were recorded at their first follow-up at 1 month, at 3 months and at the final follow-up visit at 12 months.
Thirty-three patients (10 males and 23 females) and a total of 35 eyes were included in our study. Fifteen out of 35 eyes (42.8%) experienced complete release of the VMT. One out of three eyes with a small full thickness macular hole (33.3%) closed post-injection. One eye developed partial thickness macular hole with spontaneous closure at 3 months, after a successful VMT release. Mean visual acuity improved by 6.2 logMAR letters and central macular thickness decreased by an average of 55μm in this group of 15 eyes that achieved VMT release. Twelve out of these 15 eyes (80%) also experienced improvement of symptoms. Despite a successful VMT release in three eyes, there was no improvement in their visual symptoms. The safety review showed that visual symptoms such as vitreous floaters and photopsia were common early after ocriplasmin injection, but rapidly resolved afterwards.
Intravitreal ocriplasmin in carefully selected patients is a promising and safe treatment option for VMT in symptomatic patients and it could represent a viable alternative to pars plana vitrectomy.
This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.
This PDF is available to Subscribers Only